Barclays Reiterates Buy Rating on Indivior Pharmaceuticals
Barclays maintains its bullish outlook on Indivior with a $46 target.
Key Points
- Barclays reiterated its buy rating on Indivior Pharmaceuticals, setting a price target of $46 per share.
- Indivior's stock trades near $37.93 with a market cap of approximately $4.48 billion and a P/E ratio of 19.45.
- Insiders have been active, with recent planned sales by executives and purchases by board members.
On June 18, 2026, Barclays analyst Glen Santangelo reiterated his buy rating on Indivior Pharmaceuticals, Inc. (NasdaqGS: INDV), setting a price target of $46. This action reflects continued confidence in the company's prospects.
Other Institutional Activity in Indivior Pharmaceuticals
Several major funds have also been active in Indivior. BlackRock, Inc. added 18,542,220 shares, bringing its total to approximately 18.5 million shares valued at about $565.17 million. Vanguard Portfolio Management LLC acquired 7,891,819 shares, ending with nearly 7.9 million shares worth approximately $240.54 million. Meanwhile, Oaktree Capital Management LP trimmed its holdings by 124,542 shares, now holding about 6.98 million shares valued at $212.88 million.
Indivior Pharmaceuticals, Inc. Stock Up 1.0%
Shares of NasdaqGS:INDV traded near $37.93. Indivior has a market cap of approximately $4.48 billion and a P/E ratio of 19.45. The stock's 52-week range has been between $13.45 and $41.00. It has a 50-day moving average of $36.07 and a 200-day moving average of $31.96. The company's current ratio stands at 0.856, with a quick ratio of 0.591, indicating some liquidity constraints.
Recent Earnings
Indivior reported revenue of $1.29 billion with a growth rate of 19.2%. Its earnings per share (EPS) was $1.95, leading to a net margin of 19.53%. The company is expected to release its next earnings report on August 6, 2026.
Insider Buying and Selling at Indivior Pharmaceuticals, Inc.
Recent insider activity at Indivior saw Chief Scientific Officer Christian Heidbreder sell 18,586 shares at an average price of $38.06 on June 11, 2026, under a planned sale. Chief Financial Officer Ryan Preblick sold 36,000 shares at $37.70 on June 8, 2026, also as part of a planned transaction. In May 2026, board members Barbara Ryan, Keith Humphreys, Juliet Thompson, and David Wheadon each purchased shares, with Wheadon buying 10,430 shares.
Analysts Set New Price Targets
On June 18, 2026, Barclays reiterated its buy rating with a $46 target. HC Wainwright & Co. previously maintained a buy rating with a $48 target on January 12, 2026. The consensus among analysts is a buy rating, with a mean target price of $51.50 based on six opinions.
About Indivior Pharmaceuticals
Indivior Pharmaceuticals, Inc. focuses on developing and selling buprenorphine-based drugs for opioid dependence. Headquartered in North Chesterfield, Virginia, the company operates in the healthcare sector, specifically in drug manufacturing. Key products include SUBLOCADE and SUBOXONE, which are used to treat substance use disorders. Indivior is led by CEO Joseph J. Ciaffoni and employs 827 people.
Bottom Line
Barclays' reiteration of a buy rating for Indivior Pharmaceuticals with a $46 target underscores the firm's positive outlook on the company's potential. The stock's current trading range and recent insider activities are important for investors to consider. As always, it's crucial to remember that analyst ratings and 13F filings are backward-looking and may not reflect current positions or future performance.
Get Indivior Pharmaceuticals, Inc. alerts
New 13F filings, insider trades, and analyst moves on $INDV, sent to your inbox. Free, and you can unsubscribe anytime.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.